Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2011-03-22
2011-03-22
Navarro, Mark (Department: 1645)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S388400
Reexamination Certificate
active
07910706
ABSTRACT:
Novel human monoclonal antibodies derived from a transgenic mouse are disclosed as well as a process for the preparation of the novel monoclonals and a therapeutic method of treating an individual for hemolytic uremic syndrome or of protecting an individual against hemolytic uremic syndrome by administration of the monoclonals to the individual in need of treatment or protection.
REFERENCES:
patent: 4689299 (1987-08-01), Insel et al.
patent: 5512282 (1996-04-01), Krivan et al.
patent: 5955293 (1999-09-01), Keusch et al.
patent: 6080400 (2000-06-01), Williams et al.
patent: WO 90/07861 (1990-07-01), None
patent: WO 93/18784 (1993-09-01), None
patent: WO 98/20903 (1998-05-01), None
patent: WO 99/69629 (1999-11-01), None
Boerlin, et al., “Associations between virulence factors of Shiga toxin-producingEscherichia coliand disease in humans”,J Clin Microbial., 37(3):497-503 (1999).
Friedrich, et al., “Escherichia coliharboring Shiga toxin 2 gene variants: frequency and association with clinical symptoms”,J Infect Dis., 185(1):74-84 (2002).
Hashimoto, et al., “Epidemic of gastrointestinal tract infection including hemorrhagic colitis attributable to Shiga toxin 1-producingEscherichia coliO118:H2 at a junior high school in Japan”,Pediatrics, 103(1):E2 (1999).
Heffernan, Human monoclonal antibody (CP101) for the prevention and treatment of HUS and associated complications caused by Shiga toxinE. coli., dated Dec. 2, 2002.
Shoeran, et al, “Stx2-specific human monoclonal antibodies protect mice against lethal infection withEscherichia coliexpressing Stx2 variants”, Infect Immun., 71(6):3125-30 (2003).
37 C.F.R. 1.132 declaration by Dr. John. M. Leong, dated Mar. 27, 2003.
37 C.F.R. 1.132 declaration by Dr. Florian Gunzer, dated Apr. 1, 2003.
37 C.F.R. 1.132 declaration by Dr. Saul Tzipori, dated Apr. 10, 2003.
Chomczynski and Sacchi, “Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction,”Anal. Biochem. 162:156-15-9 (1987).
Donohue-Rolfe et al. “Escherichia coliO157:H7 strains that express Shiga toxin (Stx) 2 alone are more neurotropic for gnotobiotic piglets than are isotypes producing only Stx1 or both Stx1 and Stx2,” J. Infectious Diseases 181(5):1825-9(2000).
Donohue-Rolfe et al. “Purification of Shiga toxin and Shiga-like toxins I and II by receptor analog affinity chromatography with immobilized P1 glycoprotein and production of cross-reactive monoclonal antibodies”Infect. Immun. 57:3888-3893 1989.
Downes, et al., “Affinity purification and characterization of Shiga-like toxin II and production of toxin-specific monoclonal antibodies,”Infect. Immun.56(8): 1926-1933 (1988).
Edwards, et al, “Vero cell neutralization and mouse protective efficacy of humanized monoclonal antibodies againstEscherichia colitoxins Stx1 and Stx2,” inEscherichia coli 157:H7 and other Shiga toxin-producing E. coli strains(Kaper, et al. eds) American Society for Microbiology: Washington D.C., pp. 338-392 (1995).
Engelman, et al.,Human Hybirdemas and Monoclonal Antibodies, New York: Plenum Press, 23-27 (1985).
Islam, et al.“Production and characterization of monoclonal antibodies with therapeutic potential against Shiga toxin,”J. Clin. Lab. Immunol. 33: 11-16 (1990).
Linton, et al. “Primary antibody-forming cells and secondary B cells are generated from separate precursor cell subpopulations” Cell 59:1049-1059 (1989).
MacLeod, et al. “Immunization of pigs with a purified Shiga-like toxin II variant toxoid,”Vet Microbial. 29(3-4):309-18 (1991).
Moore, et al., “Production of a Shiga-like cytotoxin byCampylobacter,” Microbial Pathogenesis4: 455-462 (1988).
Ol, et al. “Chimeric Antibodies,”Biotechniques4(3): 214-226 (1986).
Ostroff, “Infections withEscherichia coliO157:H7 in Washington State. The first year of state wide disease surveillance,”JAMA. 262(3):355-9 (1989).
Ostroff, “Toxin genotypes and plasmid profiles as determinants of systemic sequelae inEscherichia coliO157:H7 infections, ”J Infect Dis. 160(6):994-8(1989).
Perera, et al., “Isolation and characterization of monoclonal antibodies to Shiga-like toxin II of enterohemorrhagicEscherichia coliand use of the monoclonal antibodies in a colony enzyme-linked immunosorbent assay,”J. Clin. Microbiol,. 26(10): 2127-2131 (1988).
Physician's Desk Reference 34thed. Charles Baker, Jr., pp. 1140-1141 (1980).
Taylor at al. “A transgenic mouse that expresses a diversity of human sequence heavy and light chain immunoglobulins,”Nucl. Acid Res. 20:6287-6295 (1992).
Tzipori et al. “The role of the eaeA gene in diarrhea and neurological complications in a gnotobiotic piglet model of enterohemorrhagicEscherichia coliinfection,”Infect. and Immun. 63:3621-3627, (1995).
Balakrishnan Ramaswamy
Donohue-Rolfe Arthur
Tzipori Saul
Navarro Mark
Pabst Patent Group LLP
Trustees of Tufts College
LandOfFree
Humanized neutralizing antibodies against hemolytic uremic... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Humanized neutralizing antibodies against hemolytic uremic..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Humanized neutralizing antibodies against hemolytic uremic... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2768643